In osteosarcoma, Dinutuximab combined with GM-CSF in recurrent patients to characterize the pharmacokinetics and toxicity (NCT02484443), and Hu3F8 along with GM-CSF in patients in remission, evaluating its effectiveness in preventing recurrence (NCT02502786). This evidence concerns the gene CSF2 and osteosarcoma.